Nov. 24, 2020—Six Vanderbilt University faculty members have been elected 2020 fellows of the American Association for the Advancement of Science, an honor bestowed upon AAAS members by their peers.
Nov. 12, 2020—Vanderbilt contributes molecular imaging data of kidney to the Human BioMolecular Atlas Program, a consortium of 18 diverse collaborative research teams across the United States and Europe.
Oct. 5, 2020—Vanderbilt researchers have identified a signaling pathway that promotes kidney fibrosis in patients with diabetes — and that could be targeted with an existing approved medication.
Jul. 25, 2019—Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.
Oct. 16, 2018—Raymond Harris, Ming-Zhi Zhang and colleagues suggest pathways activated by the epidermal growth factor receptor may be promising targets for treating diabetic kidney disease.
Sep. 28, 2018—Biochemistry professor Richard Caprioli, director of the Mass Spectrometry Research Center, and Jeff Spraggins, research assistant professor of biochemistry, and their team will build a platform to molecularly characterize cells.
Aug. 17, 2018—ianchun Chen, Raymond Harris and colleagues have identified a potential new target for treating acute kidney injury.
Jun. 28, 2018—T. Alp Ikizler, MD, an internationally known expert on the nutritional and metabolic aspects of kidney disease, will succeed Raymond Harris, MD, as director of the Department of Medicine’s Division of Nephrology and Hypertension in the Vanderbilt University School of Medicine effective July 1.
Oct. 13, 2017—Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.
Sep. 28, 2017—Vanderbilt’s Division of Nephrology and Hypertension has received a five-year, $5 million federal grant to provide core research services in the fight against kidney disease.
Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
Nov. 12, 2015—A signaling protein that is essential for recovery from acute kidney injury works by increasing the population of tissue-repairing immune cells.